Effect of Amalaki (Emblica officinalis Gaertn) swarasa bhavitha Haridra (Curcuma longa Linn.) churna in Diabetic dyslipidemia - A case report

Backround: Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased sugar levels, triglyceride, low-density lipoproteins (LDL) levels and with decreased high-density lipoprotein (HDL) particles in the body. The lipid changes associated with type 2 diabetes mellitus (T2DM) are attributed to increased free fatty acid flux secondary to insulin resistance. According to National Nutrition Monitoring Bureau (NNMB) 34% men and 33.6% women come under the category of both diabetic and dyslipidemia. Both diabetes and dyslipidemia are indeed common health concerns today. These are often linked and share risk factors and diabetes can lead to dyslipidemia over time. Case presentation: A 55year old male patient presented with complaints of the numbness of left little toe, increased sweating and hunger. Initial evaluation of blood sugar and lipid profile suggests as a known case of diabetes mellitus and dyslipidemia. He was advised to administer Amalaki swarasa bhavitha haridra churna capsules (2 x 500mg bd) with lukewarm water after food for 3 months. Assessment of FBS, PPBS and lipid profile were done at the end of each month. HbA1C was done prior to the treatment and after the completion of 3 months. Conclusion: The combination of drug Haridra and Amalaki seems to be simple, safe and cost effective, easily available, without any adverse drug reactions (ADR) that can be administered in diabetic and dyslipidemic patients. The study drug was effective in reducing both the blood sugar levels and lipid profile value to a normal range in a patient with diabetic dyslipidemia.